Prof. Alexander Hoischen leads the research group ‘Genomic Technologies for Immune-mediated and Infectious Diseases’ (https://www.immuno-genomics.com/; Genomic technologies for immune-mediated and infectious diseases - Radboudumc) at the Radboud University Medical Center, Nijmegen, The Netherlands. This group has made significant contributions by pioneering genomic technologies across many rare diseases, with a particular focus on rare immune diseases. We focused on developing novel genomic approaches for studying rare genetic diseases (RD) and translating these technological innovations into clinical applications, including the early adoption of exome sequencing and subsequent pioneering of long-read genome sequencing and optical genome mapping (OGM). Consequently, our institution is one of the first globally, to use long-read genome sequencing as a first tier generic assay across all rare diseases (launched Oct 2025, aim in 1st year 5,000 clinical long-read genomes). Our current research is focused on immunology and rare immune-mediated and infectious diseases, with a major aim to discover new Inborn Errors of Immunity (IEI). Our work led to the discovery of the X-linked TLR7 deficiency that predisposes to severe COVID-19. Alex is involved in international rare disease programs, most prominently he led a work-package for Solve-RD (H2020), followed-up by an ERDERA work-package lead (2024-2031). He is also supported by a ZonMW VICI grant (NWO, 1.5M€, 5 years, starting Sept-2024), which will strengthen innovative science for immune diseases. He serves as the Chief-Innovation officer of the Department of Human Genetics and Scientific Director of the Radboudumc Genomics Technology Center.